On a mechanistic level, increased interaction of hypoglycosylated E-cadherin complexes with PP2A resulted in reduced association of PP2A with ZO-1 and claudin-1. the association of PP2A with these junctional complexes. because its deficiency results in the mislocalization of key tight junctional components, leading to transepithelial water loss and perinatal death [31]. Our previous studies have shown that modification of E-cadherin ectodomains (ECs) 4 and 5 with N-glycans impacts the composition and stability of E-cadherin scaffolds. In particular, removal of complex N-glycans from EC Zearalenone 4 promotes the association of E-cadherin with -catenin and vinculin and enhances their interaction with the actin cytoskeleton [32]. Likewise, hypoglycosylated E-cadherin interacts more readily with dynein and PP2A, thus promoting the interaction of AJs with MTs. N-glycosylation of E-cadherin is physiologically significant because it is subject to changes with cell density [32, 33] and epithelial phenotype development [34]. In sparse Madin-Darby canine kidney (MDCK) cells lacking mature AJs, E-cadherin is primarily N-glycosylated with complex oligosaccharides, while E-cadherin N-glycosylation is greatly reduced in dense cultures with stable junctional complexes [32, 33]. Our most recent studies have shown that hyperglycosylation of E-cadherin in oral cancer cells is associated with the destabilization of AJs and TJs, cellular discohesion and tumor spread [23]. N-glycosylation status of proteins is regulated by the level of expression of the DPAGT1 gene encoding dolichol-P-dependent N-acetylglucosamine-1-phosphate-transferase [35C37]. Evolutionarily conserved and essential for viability, DPAGT1 initiates the synthesis of the lipid-linked oligosaccharide (LLO) precursor for protein N-glycosylation in the endoplasmic reticulum (ER) [38C41]. On a mechanistic level, DPAGT1 expression determines the amount of LLO and, therefore, the extent of protein N-glycosylation [35, 36]. DPAGT1 is regulated with growth; it displays abundant expression in proliferating cells that is diminished in dense cultures [42, 43]. Thus, N-glycosylation status of E-cadherin is directly related to the level of DPAGT1 expression. Because the formation of AJs precedes TJ assembly, and because E-cadherin N-glycans destabilize AJs, we examined whether E-cadherin N-glycans affected the organization and function of TJs. In the present study, we show that partial inhibition of DPAGT1 in MDCK cells led to reduced N-glycosylation of E-cadherin, stabilization of AJs, enhancement of TJs, increased cell compaction and diminished proliferation. Similar results were obtained with MDCK cells transfected with the hypoglycosylated E-cadherin variant, V13 [32], indicating that intracellular adhesion was driven by diminished N-glycosylation of E-cadherin. On a mechanistic level, increased interaction of hypoglycosylated E-cadherin complexes with PP2A resulted in reduced association of PP2A with ZO-1 and claudin-1. This promoted the formation of ZO-1-occludin-claudin-1 complexes concomitant with an increase in transepithelial resistance (TER). Collectively, our studies provide evidence that E-cadherin N-glycans inhibit intercellular adhesion by excluding PP2A from AJs and facilitating its association with TJs. Mouse monoclonal to RAG2 Materials and Methods Reagents and antibodies Polyclonal antibody to the conserved 11 amino acid C-terminal sequence of DPAGT1 was prepared commercially (Covance). Monoclonal antibody to the cytoplasmic region of human E-cadherin, as well as monoclonal antibodies to -catenin, -catenin, -catenin, PP2A-C, ZO-1 and IgG isotype controls were obtained from BD Transduction Laboratories. Monoclonal antibody to gp135 Zearalenone (hybridoma supernatant, 3F2) was a gift from George Ojakian (SUNY Downstate Medical Center, Brooklyn, NY). Monoclonal antibodies to the myc tag and vinculin (clone V284) were from Cell Signaling and Upstate Biotechnology, respectively. Monoclonal antibody to actin (pan Ab-5, clone ACTN05) was from Zearalenone NeoMarkers. Polyclonal antibodies to occludin and claudin-1 were from Zymed. Antibodies to calnexin were obtained from Abcam. Rhodamine-phalloidin was obtained from Molecular Probes. Secondary antibodies included goat anti-mouse or anti-rabbit IgG derivatized with either fluorescein isothiocyanate or Alexa Fluor (Molecular Probes). Horseradish peroxidase-conjugated secondary antibodies were from Amersham Biosciences. Protein G Sepharose and Protein A Agarose beads were purchased from Sigma. Trypan blue was. Zearalenone